Ⅲ、Ⅳ型成骨不全症患者种植治疗进展

doi:10.12337/zgkqzzxzz.2023.10.013

摘要/Abstract

摘要： 成骨不全症患者缺牙概率接近正常人群2倍,成骨不全症患者缺牙后,寻找一种合适的修复方式是有必要的。此类患者多伴有骨质脆而疏松,且部分重型患者需长期使用双膦酸盐类药物,这对种植修复带来了挑战。目前各型成骨不全症患者接受种植治疗的案例逐渐增多,本文主要对现有的III、IV型两类重型成骨不全症患者种植案例的病史、手术步骤及随访预后进行回顾,结合相关文献研究,认为此类患者接受种植治疗是可行的,可为III、IV型成骨不全症患者进行种植修复的临床医师提供参考。

关键词: 罕见病, 种植义齿, 成骨不全症, 骨结合, 双膦酸盐, 种植体周病

Abstract: Patients with osteogenesis imperfecta have twice the risk of tooth loss compared to the general population. It is necessary to find a suitable method for restoration after tooth loss in these patients. Many of these patients have fragile and porous bones, and some severe cases require long-term use of bisphosphonates, which poses a challenge for implant restorations. Currently, there is an increasing number of cases involving implant treatments for patients with types III and IV severe osteogenesis imperfecta. This article reviews the medical histories, surgical procedures, and follow-up outcomes of implant treatments of patients with these two types. Based on relevant literature research, it is deemed feasible for these patients to undergo implant treatments, providing a reference for clinicians performing implant restorations in patients with types III and IV osteogenesis imperfecta.

Key words: Rare diseases, Implant prosthesis, Osteogenesis imperfecta, Osseointegration, Bisphosphonates, Peri-implant diseases

田聪,等周立伟,等李孟铨. Ⅲ、Ⅳ型成骨不全症患者种植治疗进展[J]. 中国口腔种植学杂志, 2023, 28(5): 371-376. DOI: 10.12337/zgkqzzxzz.2023.10.013

Tian Cong, Zhou Liwei, Li Mengquan. Progress of implant treatment for patients with type III and IV osteogenesis imperfecta[J].Chinese Journal of Oral Implantology, 2023, 28(5): 371-376.DOI: 10.12337/zgkqzzxzz.2023.10.013.

参考文献

[1] Forlino A, Cabral WA, Barnes AM, et al.New perspectives on osteogenesis imperfecta[J]. Nat Rev Endocrinol, 2011,7(9):540-557. DOI: 10.1038/nrendo.2011.81.
[2] Barnes AM, Chang W, Morello R, et al.Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta[J]. N Engl J Med, 2006,355(26):2757-2764. DOI: 10.1056/NEJMoa063804.
[3] Franzone JM, Shah SA, Wallace MJ, et al.Osteogenesis imperfecta: a pediatric orthopedic perspective[J]. Orthop Clin North Am, 2019,50(2):193-209. DOI: 10.1016/j.ocl.2018.10.003.
[4] Mortier GR, Cohn DH, Cormier-Daire V, et al.Nosology and classification of genetic skeletal disorders: 2019 revision[J]. Am J Med Genet A, 2019,179(12):2393-2419. DOI: 10.1002/ajmg.a.61366.
[5] Marom R, Rabenhorst BM, Morello R.Osteogenesis imperfecta: an update on clinical features and therapies[J]. Eur J Endocrinol, 2020,183(4):R95-R106. DOI: 10.1530/EJE-20-0299.
[6] Saeves R, Lande Wekre L, Ambjørnsen E, et al.Oral findings in adults with osteogenesis imperfecta[J]. Spec Care Dent, 2009,29(2):102-108. DOI: 10.1111/j.1754-4505.2008.00070.x.
[7] Tuominen R, Ranta K, Paunio I.Wearing of removable partial dentures in relation to dental caries[J]. J Oral Rehabil, 1988,15(6):515-520. DOI: 10.1111/j.1365-2842.1988.tb00187.x.
[8] Mills LA, Aitken SA, Simpson A.The risk of non-union per fracture: current myths and revised figures from a population of over 4 million adults[J]. Acta Orthop, 2017,88(4):434-439. DOI: 10.1080/17453674.2017.1321351.
[9] Munk SA, Harsevoort GJ, Gooijer K, et al.Incidence and nonunion rates of tibial fractures in adults with osteogenesis imperfecta: a retrospective cohort study of 402 patients with 42 fractures at an expert clinic[J]. BMC Musculoskelet Disord, 2022,23(1):1077. DOI: 10.1186/s12891-022-05966-7.
[10] Goudriaan WA, Harsevoort GJ, van Leeuwen M, et al. Incidence and treatment of femur fractures in adults with osteogenesis imperfecta: an analysis of an expert clinic of 216 patients[J]. Eur J Trauma Emerg Surg, 2020,46(1):165-171. DOI: 10.1007/s00068-018-1005-9.
[11] Agarwal V, Joseph B.Non-union in osteogenesis imperfecta[J]. J Pediatr Orthop B, 2005,14(6):451-455. DOI: 10.1097/01202412-200511000-00013.
[12] Azzam KA, Rush ET, Burke BR, et al.Mid-term results of femoral and tibial osteotomies and fassier-duval nailing in children with osteogenesis imperfecta[J]. J Pediatr Orthop, 2018,38(6):331-336. DOI: 10.1097/BPO.0000000000000824.
[13] Oelerich O, Kleinheinz J, Bohner L, et al.Dental implants in people with osteogenesis imperfecta: a systematic review[J]. Int J Environ Res Public Health, 2022,19(3):1563. DOI: 10.3390/ijerph19031563.
[14] Jensen JL, Brox HT, Storhaug K, et al.Dental implants in patients with osteogenesis imperfecta: a retrospective and prospective study with review of the literature[J]. Oral Surg, 2011, 4(3): 105-114.DOI: 10.1111/j.1752-248X.2011.01124.x.
[15] Wannfors K, Johansson C, Donath K.Augmentation of the mandible via a “tent-pole” procedure and implant treatment in a patient with type III osteogenesis imperfecta: clinical and histologic considerations[J]. Int J Oral Maxillofac Implants, 2009,24(6):1144-1148.
[16] Fogh FM, Jensen SS, Kofod T, et al.Dental implants in patients with osteogenesis imperfecta - clinical and radiographic outcome in six patients[J]. Oral Health Prev Dent, 2023,21(1):33-40. DOI: 10.3290/j.ohpd.b3858615.
[17] Lee CY, Ertel SK.Bone graft augmentation and dental implant treatment in a patient with osteogenesis imperfecta: review of the literature with a case report[J]. Implant Dent, 2003,12(4):291-295. DOI: 10.1097/01.id.0000086481.84152.42.
[18] Caicedo-Rubio M, Ferrés-Amat E, Ferrés-Padró E.Implant-supported fixed prostheses in a patient with osteogenesis imperfecta: a 4-year follow-up[J]. J Clin Exp Dent,2017,9(12):e1482-e1486.DOI: 10.4317/jced.53958.
[19] Myint M, Stovne SA, Saeves T, et al.Dental implants in individuals with osteogenesis imperfecta: a 6‐year follow‐up study[J]. Oral Surg, 2019, 12(3): 272-277.
[20] Prabhu N, Duckmanton N, Stevenson AR, et al.The placement of osseointegrated dental implants in a patient with type IV osteogenesis imperfecta: a 9-year follow-up[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2007,103(3):349-354. DOI: 10.1016/j.tripleo.2006.06.006.
[21] Kang DY, Kim M, Lee SJ, et al.Early implant failure: a retrospective analysis of contributing factors[J]. J Periodontal Implant Sci, 2019,49(5):287-298. DOI: 10.5051/jpis.2019.49.5.287.
[22] Prabhu SS, Fortier K, May MC, et al.Implant therapy for a patient with osteogenesis imperfecta type I: review of literature with a case report[J]. Int J Implant Dent, 2018,4(1):36. DOI: 10.1186/s40729-018-0148-0.
[23] Lewis M K, Stoker N G.Surgical management of the patient with osteogenesis imperfecta[J]. J Oral Maxillofac Surg, 1987, 45(5): 430-437.DOI: 10.1016/0278-2391(87)90011-5.
[24] Prado HV, Teixeira SA, Rabello F, et al.Malocclusion in individuals with osteogenesis imperfecta: a systematic review and meta-analysis[J]. Oral Dis, 2022,28(2):314-325. DOI: 10.1111/odi.13715.
[25] De Nova-García MJ, Bernal-Barroso F, Mourelle-Martínez MR, et al. Evaluation of the severity of malocclusion in children with osteogenesis imperfecta[J]. J Clin Med, 2022,11(16):4862. DOI: 10.3390/jcm11164862.
[26] Bernhardt O, Krey KF, Daboul A, et al.New insights in the link between malocclusion and periodontal disease[J]. J Clin Periodontol, 2019,46(2):144-159. DOI: 10.1111/jcpe.13062.
[27] Bertolini MM, Del Bel Cury AA, Pizzoloto L, et al. Does traumatic occlusal forces lead to peri-implant bone loss? A systematic review[J]. Braz Oral Res, 2019,33(suppl 1):e069. DOI: 10.1590/1807-3107bor-2019.vol33.0069.
[28] Tauer JT, Robinson ME, Rauch F.Osteogenesis imperfecta: new perspectives from clinical and translational research[J]. JBMR Plus, 2019,3(8):e10174. DOI: 10.1002/jbm4.10174.
[29] Drake MT, Clarke BL, Khosla S.Bisphosphonates: mechanism of action and role in clinical practice[J]. Mayo Clin Proc, 2008,83(9):1032-1045. DOI: 10.4065/83.9.1032.
[30] Ruggiero SL, Dodson TB, Aghaloo T, et al.American Association of Oral and Maxillofacial surgeons’ position paper on medication-related osteonecrosis of the jaws-2022 update[J]. J Oral Maxillofac Surg, 2022, 80(5): 920-943.DOI: 10.1016/j.joms.2022.02.008
[31] Contaldo M, Luzzi V, Ierardo G, et al.Bisphosphonate-related osteonecrosis of the jaws and dental surgery procedures in children and young people with osteogenesis imperfecta: a systematic review[J]. J Stomatol Oral Maxillofac Surg, 2020,121(5):556-562. DOI: 10.1016/j.jormas.2020.03.003.
[32] Goss A, Bartold M, Sambrook P, et al.The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a South Australian case series[J]. J Oral Maxillofac Surg, 2010,68(2):337-343. DOI: 10.1016/j.joms.2009.09.037.
[33] Stavropoulos A, Bertl K, Pietschmann P, et al.The effect of antiresorptive drugs on implant therapy: systematic review and meta-analysis[J]. Clin Oral Implants Res, 2018,29(Suppl 18):S54-S92. DOI: 10.1111/clr.13282.
[34] Lazarovici TS, Yahalom R, Taicher S, et al.Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients[J]. J Oral Maxillofac Surg, 2009,67(4):850-855. DOI: 10.1016/j.joms.2008.11.015.
[35] Bamias A, Kastritis E, Bamia C, et al.Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors[J]. J Clin Oncol, 2005, 23(34): 8580-8587.
[36] Cremers S, Drake MT, Ebetino FH, et al.Pharmacology of bisphosphonates[J]. Br J Clin Pharmacol, 2019, 85(6): 1052-1062.DOI: 10.1111/bcp.13867.
[37] Gelazius R, Poskevicius L, Sakavicius D, et al.Dental implant placement in patients on bisphosphonate therapy: a systematic review[J]. J Oral Maxillofac Res, 2018,9(3):e2. DOI: 10.5037/jomr.2018.9302.
[38] Fu JH, Wang HL.Breaking the wave of peri-implantitis[J]. Periodontol 2000, 2020,84(1):145-160. DOI: 10.1111/prd.12335.
[39] Ferreira SD, Martins CC, Amaral SA, et al.Periodontitis as a risk factor for peri-implantitis: systematic review and meta-analysis of observational studies[J]. J Dent, 2018,79:1-10. DOI: 10.1016/j.jdent.2018.09.010.
[40] Di Murro B, Canullo L, Pompa G, et al.Prevalence and treatment of retrograde peri-implantitis: a retrospective cohort study covering a 20-year period[J]. Clin Oral Investig, 2021,25(7):4553-4561. DOI: 10.1007/s00784-020-03769-5.
[41] Nguyen H, Vu DC, Nguyen DM, et al.Dentinogenesis Imperfecta and caries in osteogenesis imperfecta among vietnamese children[J]. Dent J (Basel), 2021,9(5):49. DOI: 10.3390/dj9050049.
[42] Di Murro B, Papi P, Di Murro C, et al.Correlation between endodontic pulpal/periapical disease and retrograde peri-implantitis: a case series[J]. Aust Endod J, 2021,47(2):358-364. DOI: 10.1111/aej.12458.
[43] Lefever D, Van Assche N, Temmerman A, et al.Aetiology, microbiology and therapy of periapical lesions around oral implants: a retrospective analysis[J]. J Clin Periodontol, 2013,40(3):296-302. DOI: 10.1111/jcpe.12045.
[44] López-Martínez F, Gómez Moreno G, Olivares-Ponce P, et al.Implants failures related to endodontic treatment. An observational retrospective study[J]. Clin Oral Implants Res, 2015, 26(9): 992-995.DOI: 10.1111/clr.12415.
[45] Dreyer H, Grischke J, Tiede C, et al.Epidemiology and risk factors of peri-implantitis: a systematic review[J]. J Periodontal Res, 2018,53(5):657-681. DOI: 10.1111/jre.12562.
[46] Xi L, Lv S, Zhang H, et al.Novel mutations in BMP1 result in a patient with autosomal recessive osteogenesis imperfecta[J]. Mol Genet Genomic Med, 2021,9(6):e1676. DOI: 10.1002/mgg3.1676.
[47] Xu XJ, Lv F, Song YW, et al.Novel mutations in BMP1 induce a rare type of osteogenesis imperfecta[J]. Clin Chim Acta, 2019,489:21-28. DOI: 10.1016/j.cca.2018.11.004.
[48] Wang J, Massoudi D, Ren Y, et al.BMP1 and TLL1 are required for maintaining periodontal homeostasis[J]. J Dent Res, 2017,96(5):578-585. DOI: 10.1177/ 0022034516686558.
[49] Mijiritsky E, Assaf HD, Kolerman R, et al.Autologous platelet concentrates (APCs) for hard tissue regeneration in oral implantology, sinus floor elevation, peri-Implantitis, socket preservation, and medication-related osteonecrosis of the jaw (MRONJ): a literature review[J]. Biology (Basel), 2022,11(9):1254. DOI: 10.3390/biology11091254.
[50] Huang G, Pan ST, Qiu JX.The clinical application of porous tantalum and its new development for bone tissue engineering[J]. Materials (Basel), 2021,14(10):2647. DOI: 10.3390/ma14102647.
[51] Bencharit S, Morelli T, Barros S, et al.Comparing initial wound healing and osteogenesis of porous tantalum trabecular metal and titanium alloy materials[J]. J Oral Implantol, 2019,45(3):173-180. DOI: 10.1563/aaid-joi-D-17-00258.